Detection of drug-resistant Mycobacterium tuberculosis strains isolated in Serbia by the genotype MTBDRsl assay

Archives of Biological Sciences

Volumn 64, Issue 4, 2012, Pages 1311-1318

  Živanović, Irena ^a   Vuković, Dragana ^a   Dakić, Ivana ^a   Stefanović, Gordana ^b   Savić, Branislava ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Extensively drug resistant tuberculosis; Geno Type MTBDRsl; Multidrug resistant tuberculosis; Mycobacterium tuberculosis

Indexed keywords

EID: 84867775209     PISSN: 03544664     EISSN: None     Source Type: Journal    
DOI: 10.2298/ABS1204311Z     Document Type: Article

References (24)

1. Alangaden, G.J., Kreiswirth, B.N., Aouad, A., Khetarpal, M., Igno, F.R., Moghazeh, S.L., Manavathu, E.K., and S.A. Lerner (1998). Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1295-1297.
2. Antonova, O.V., Gryadunov, D.A,. Lapa, S.A., Kuz'min, A.V., Larionova, E.E., Smirnova, T.G., Nosova, E.Y,. Skotnikova, O.I,. Chernousova, L.N., Moroz, A.M., Zasedatelev, A.S., and V.M. Mikhailovich (2008). Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull. Exp. Biol. Med. 145, 108-113.
3. Brossier, F., Veziris, N., Aubry, A., Jarlier, V., and W. Sougakoff (2010). Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48, 1683-1689.
4. Caminero, J.A. (2010). Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int. J. Tuberc. Lung Dis. 14, 382-390.
5. Hazbon, M.H., Bobadilla, V.M., Guerrero, M.I., Varma-Basil, M., Filliol, I., Cavatore, M., Colangeli, R., Safi, H., Billman-Jacobe, H., Lavender, C., Fyfe, J., Garcia-Garcia, L., Davidow, A., Brimacombe, M., Leon, C.I., Porras, T., Bose, M., Chaves, F., Eisenach, K.D., Sifuentes-Osornio, J., Ponce de Leon, A., Cave, M.D. and D. Alland (2005). Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob. Agents Chemother. 49, 3794-3802.
6. Hillemann, D., Rüsch-Gerdes, S., and E. Richter (2009). Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47, 1767-1772.
7. Huang, W.L., Chi, T.L., Wu, M.H., and R. Jou (2011). Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrugresistant Mycobacterium tuberculosis. J. Clin. Microbiol. 49, 2502-2508.
8. Johnston, J.C., Shahidi, N.C., Sadatsafavi, M., and J.M. Fitzgerald (2009). Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 4, e6914.
9. Jugheli, L., Bzekalava, N., Rijk, P., Fissette, K., Portaels, F., and L. Rigouts (2009). High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 53, 5064-5068.
10. Kiet, V.S., Lan, N.T., An, D.D., Dung, N.H., Hoa, D.V., Chau, N.V., Chinh, N.T., Farrar, J., and M. Caws (2010). Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48, 2934-2939.
11. Maus, C.E., Plikaytis, B.B., and T.M. Shinnick (2005). Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 3192-3197.
12. Mokrousov, I., Otten, T., Vyshnevskiy, B., and O. Narvskaya (2002). Detection of embB306 mutations in ethambutolsusceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing. J. Clin. Microbiol. 40, 3810-3813.
13. Mokrousov, I., Otten, T., Manicheva, O., Potapova, Y., Vishnevsky, B., Narvskaya, O., and N. Rastogi (2008). Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52, 2937-2939.
14. Parsons, L.M., Somoskövi, A., Gutierrez, C., Lee, E., Paramasivan, C.N., Abimiku, A., Spector, S., Roscigno, G., and J. Nkengasong (2011). Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin. Microbiol. Rev. 24, 314-350.
15. Plinke, C., Rüsch-Gerdes, S., and S. Niemann (2006). Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 50, 1900-1902.
16. Safi, H., Sayers, B., Hazbon, M.H. and D. Alland (2008). Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob. Agents Chemother. 52, 2027-2034.
17. Sotgiu, G., Ferrara, G., Matteelli, A., Richardson, M.D., Centis, R., Ruesch-Gerdes, S., Toungoussova, O., Zellweger, J-P., Spanevello, A., Cirillo, D., Lange, C., and G.B. Migliori (2009). Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J. 33, 871-881.
18. Starks, A.M., Gumusboga, A., Plikaytis, B.B., Shinnick, T.M., and J.E. Posey (2009). Mutations at embB codon 306 are an im portant molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53, 1061-1066.
19. Woods, G., Warren, N.G., and C.B. Inderlied (2007). Susceptibility test methods: mycobacteria, norcardia, and other actinomycetes, In: Manual of Clinical Microbiology, 9th (Eds. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, and M.A. Pfaller), 1223-1247. ASM Press, Washington, DC.
20. World Health Organization (2008). Anti-tuberculosis drug resistance in the world. Fourth Global Report. WHO/HTM/ TB/2008.394. World Health Organization/International Union against Tuberculosis and Lung Disease (WHO/ UNION) Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2002-2007. World Health Organization, Geneva, Switzerland.
21. World Health Organization (2009). Guidelines for surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2009.422 World Health Organization, Geneva, Switzerland.
22. World Health Organization (2011a). Global Tuberculosis Control 2011. WHO/HTM/TB/2011.16. World Health Organization, Geneva, Switzerland.
23. World Health Organization (2011b). Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO/HTM/ TB/2011.3. World Health Organization, Geneva, Switzerland.
24. Zhang, Y. and W.W. Yew (2009). Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13, 1320-1330.